Anders Bjartell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5153557/publications.pdf

Version: 2024-02-01

285	13,028	23565	30081
papers	citations	58 h-index	103 g-index

294	294	294	16012
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine, 2019, 381, 13-24.	27.0	904
2	Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. European Urology, 2013, 63, 597-603.	1.9	450
3	Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. European Urology, 2015, 68, 216-225.	1.9	347
4	ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. European Urology, 2009, 56, 275-286.	1.9	332
5	Carbon Monoxide Expedites Metabolic Exhaustion to Inhibit Tumor Growth. Cancer Research, 2013, 73, 7009-7021.	0.9	295
6	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	1.9	278
7	Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells. Cancer Research, 2011, 71, 1956-1967.	0.9	244
8	Advances in Magnetic Resonance Imaging: How They Are Changing the Management of Prostate Cancer. European Urology, 2011, 59, 962-977.	1.9	225
9	Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Journal of Clinical Oncology, 2021, 39, 2294-2303.	1.6	218
10	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948.	3.7	209
11	The Mutational Landscape of Prostate Cancer. European Urology, 2013, 64, 567-576.	1.9	203
12	Positive Surgical Margins in Radical Prostatectomy: Outlining the Problem and Its Long-Term Consequences. European Urology, 2009, 55, 87-99.	1.9	201
13	The Human Cationic Antimicrobial Protein (hCAP-18) Is Expressed in the Epithelium of Human Epididymis, Is Present in Seminal Plasma at High Concentrations, and Is Attached to Spermatozoa. Infection and Immunity, 2000, 68, 4297-4302.	2.2	200
14	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ: British Medical Journal, 2010, 341, c4521-c4521.	2.3	195
15	Epigenetics in Prostate Cancer: Biologic and Clinical Relevance. European Urology, 2011, 60, 753-766.	1.9	187
16	Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. European Urology, 2009, 56, 594-605.	1.9	174
17	A Systematic Review of the Volumeâ€“Outcome Relationship for Radical Prostatectomy. European Urology, 2013, 64, 786-798.	1.9	172
18	A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index. European Urology, 2012, 62, 78-84.	1.9	158

#	Article	IF	Citations
19	Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications. European Urology, 2009, 55, 1321-1332.	1.9	155
20	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 2019, 76, 790-813.	1.9	151
21	Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. European Urology, 2011, 60, 1045-1054.	1.9	148
22	miRâ€34c is downregulated in prostate cancer and exerts tumor suppressive functions. International Journal of Cancer, 2010, 127, 2768-2776.	5.1	145
23	Tumor markers in prostate cancer I: Blood-based markers. Acta OncolÃ³gica, 2011, 50, 61-75.	1.8	144
24	Interleukinâ€6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. International Journal of Cancer, 2008, 122, 1521-1529.	5.1	142
25	Alpha1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatc hyperplasia. Urology, 1994, 43, 427-434.	1.0	133
26	FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene, 1999, 18, 2755-2761.	5.9	133
27	Neuroendocrine Differentiation in Prostatic Carcinoma During Hormonal Treatment. Urology, 1998, 51, 585-589.	1.0	131
28	The Proteome of Primary Prostate Cancer. European Urology, 2016, 69, 942-952.	1.9	122
29	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 469-476.	6.4	119
30	Downsides of Robot-assisted Laparoscopic Radical Prostatectomy: Limitations and Complications. European Urology, 2010, 57, 735-746.	1.9	112
31	Multicomponent Moraxella catarrhalis outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells. Cellular Microbiology, 2011, 13, 432-449.	2.1	112
32	Degree of Preservation of the Neurovascular Bundles During Radical Prostatectomy and Urinary Continence 1 Year after Surgery. European Urology, 2015, 67, 559-568.	1.9	107
33	Functional Magnetic Resonance Imaging in Prostate Cancer. European Urology, 2009, 55, 801-814.	1.9	103
34	Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clinical Cancer Research, 2005, 11, 520-8.	7.0	89
35	Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Molecular Human Reproduction, 2002, 8, 805-810.	2.8	87
36	The proinflammatory CXC-chemokines GRO-Î±/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. International Journal of Colorectal Disease, 2007, 22, 1421-1427.	2.2	87

#	Article	IF	Citations
37	Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology, 1993, 42, 502-510.	1.0	86
38	Neurogenic origin of human prostate endocrine cells. Urology, 1999, 53, 1041-1048.	1.0	86
39	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 944.	7.1	86
40	A Contemporary Update on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy Specimens. European Urology, 2012, 62, 20-39.	1.9	85
41	A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 255-261.	2.5	84
42	Short-term Results after Robot-assisted Laparoscopic Radical Prostatectomy Compared to Open Radical Prostatectomy. European Urology, 2015, 67, 660-670.	1.9	84
43	Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells. PLoS ONE, 2011, 6, e22118.	2.5	81
44	Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the MalmÃ¶ Diet and Cancer cohort. American Journal of Clinical Nutrition, 2012, 96, 1409-1418.	4.7	80
45	miQâ€”A novel microRNA based diagnostic and prognostic tool for prostate cancer. International Journal of Cancer, 2013, 132, 2867-2875.	5.1	79
46	Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells. Journal of Biological Chemistry, 2014, 289, 15969-15978.	3.4	78
47	Expression of STAT3 in Prostate Cancer Metastases. European Urology, 2017, 71, 313-316.	1.9	78
48	FGFâ€8 is involved in bone metastasis of prostate cancer. International Journal of Cancer, 2008, 123, 22-31.	5.1	76
49	Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis. Journal of the National Cancer Institute, 2008, 100, 1022-1036.	6.3	76
50	Upregulation of miR-96 Enhances Cellular Proliferation of Prostate Cancer Cells through FOXO1. PLoS ONE, 2013, 8, e72400.	2.5	76
51	Galiellalactone is a novel therapeutic candidate against hormoneâ€refractory prostate cancer expressing activated Stat3. Prostate, 2008, 68, 269-280.	2.3	75
52	Characterization and Localization of Cysteine-Rich Secretory Protein 3 (CRISP-3) in the Human Male Reproductive Tract. Journal of Andrology, 2005, 26, 333-342.	2.0	71
53	Increased Expression of Tumor-Associated Trypsin Inhibitor, TATI, in Prostate Cancer and in Androgen-Independent 22Rv1 Cells. European Urology, 2007, 52, 1670-1681.	1.9	70
54	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1518-1530.	10.7	69

#	Article	IF	Citations
55	A prospective study on dietary fat and incidence of prostate cancer (MalmÃ¶, Sweden). Cancer Causes and Control, 2007, 18, 1107-1121.	1.8	68
56	Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 91-98.	1.6	64
57	Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial. European Urology, 2018, 73, 618-627.	1.9	62
58	Cystatin C Is Downregulated in Prostate Cancer and Modulates Invasion of Prostate Cancer Cells via MAPK/Erk and Androgen Receptor Pathways. PLoS ONE, 2009, 4, e7953.	2.5	62
59	Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. European Urology Oncology, 2018, 1, 353-360.	5.4	61
60	Toward Next Generation Plasma Profiling via Heat-induced Epitope Retrieval and Array-based Assays. Molecular and Cellular Proteomics, 2010, 9, 2497-2507.	3.8	60
61	Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate, 2002, 53, 50-59.	2.3	59
62	Î²-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochemical and Biophysical Research Communications, 2005, 333, 555-561.	2.1	59
63	Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. Journal of Leukocyte Biology, 2010, 89, 177-187.	3.3	58
64	Thromboembolic Complications in 3,544 Patients Undergoing Radical Prostatectomy with or without Lymph Node Dissection. Journal of Urology, 2015, 193, 117-125.	0.4	58
65	Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS ONE, 2017, 12, e0184418.	2.5	58
66	Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial. European Urology, 2018, 74, 816-824.	1.9	58
67	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
68	miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. Carcinogenesis, 2015, 36, 858-866.	2.8	56
69	Elevated levels and distinct patterns of expression of A-type cyclins and their associated cyclin-dependent kinases in male germ cell tumors. International Journal of Cancer, 2004, 108, 654-664.	5.1	55
70	A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. Oncogene, 2005, 24, 6385-6393.	5.9	55
71	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 595-608.	7.0	55
72	Expression of prostateâ€specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. International Journal of Cancer, 2005, 113, 290-297.	5.1	54

#	Article	IF	Citations
73	Integration of ERG gene mapping and geneâ€expression profiling identifies distinct categories of human prostate cancer. BJU International, 2009, 103, 1256-1269.	2.5	54
74	Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers. Acta OncolÃ³gica, 2011, 50, 76-84.	1.8	53
75	Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 436-445.	1.6	51
76	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51
77	Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies. Luminescence, 2000, 15, 389-397.	2.9	49
78	Î²2-syntrophin and Par-3 promote an apicobasal Rac activity gradient at cellâ€“cell junctions by differentially regulating Tiam1 activity. Nature Cell Biology, 2012, 14, 1169-1180.	10.3	49
79	Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate, 2005, 63, 324-329.	2.3	47
80	Elevated Level of Wnt5a Protein in Localized Prostate Cancer Tissue Is Associated with Better Outcome. PLoS ONE, 2011, 6, e26539.	2.5	47
81	The STAT3 inhibitor galiellalactone inhibits the generation of MDSCâ€like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. Prostate, 2019, 79, 1611-1621.	2.3	47
82	Expression and Characterization of Trypsinogen Produced in the Human Male Genital Tract. American Journal of Pathology, 2000, 157, 2011-2021.	3.8	46
83	Evaluation of Multiple Riskâ€“Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men. European Urology, 2012, 61, 471-477.	1.9	46
84	Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. European Urology, 2021, 80, 650-660.	1.9	46
85	The Antibacterial Chemokine MIG/CXCL9 Is Constitutively Expressed in Epithelial Cells of the Male Urogenital Tract and Is Present in Seminal Plasma. Journal of Interferon and Cytokine Research, 2008, 28, 191-196.	1.2	45
86	Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 41-45.	5.0	45
87	Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate, 2006, 66, 591-603.	2.3	44
88	The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. European Urology, 2016, 69, 400-404.	1.9	43
89	Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. PLoS ONE, 2016, 11, e0155901.	2.5	43
90	High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagnostic Pathology, 2011, 6, 91.	2.0	42

#	Article	IF	Citations
91	Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-Î³. Journal of Leukocyte Biology, 2004, 76, 685-691.	3.3	41
92	The Molecular Evolution of Castration-resistant Prostate Cancer. European Urology Focus, 2016, 2, 506-513.	3.1	41
93	Cartilage oligomeric matrix protein promotes prostate cancer progression by enhancing invasion and disrupting intracellular calcium homeostasis. Oncotarget, 2017, 8, 98298-98311.	1.8	40
94	A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. European Urology, 2022, 81, 285-293.	1.9	40
95	Oncological and functional outcomes 1 year after radical prostatectomy for veryâ€lowâ€risk prostate cancer: results from the prospective <scp>LAPPRO</scp> trial. BJU International, 2016, 118, 205-212.	2.5	38
96	Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy. European Urology Focus, 2019, 5, 389-398.	3.1	38
97	Male infertility and prostate cancer risk: a nested caseâ€“control study. Cancer Causes and Control, 2010, 21, 1635-1643.	1.8	37
98	Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Research, 2016, 6, 23.	2.5	37
99	Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. Targeted Oncology, 2020, 15, 301-315.	3.6	37
100	ENSAM: Europium Nanoparticles for Signal Enhancement of Antibody Microarrays on Nanoporous Silicon. Journal of Proteome Research, 2008, 7, 1308-1314.	3.7	36
101	miR-183 in Prostate Cancer Cells Positively Regulates Synthesis and Serum Levels of Prostate-specific Antigen. European Urology, 2015, 68, 581-588.	1.9	35
102	Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. Prostate, 2003, 57, 196-204.	2.3	34
103	Carcinoma of the prostate with Cushing's syndrome. European Journal of Endocrinology, 1988, 119, 506-516.	3.7	33
104	Cystatin C Is Highly Expressed in the Human Male Reproductive System. Journal of Andrology, 2004, 25, 564-572.	2.0	33
105	Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract. Journal of Reproductive Immunology, 2008, 79, 37-43.	1.9	33
106	PBX3 is a putative biomarker of aggressive prostate cancer. International Journal of Cancer, 2016, 139, 1810-1820.	5.1	32
107	The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. PLoS ONE, 2016, 11, e0156497.	2.5	32
108	Semiquantitative morphology of human prostatic development and regional distribution of prostatic neuroendocrine cells. Prostate, 2001, 46, 108-115.	2.3	31

#	Article	IF	Citations
109	Expression and Production of the CXC Chemokine Growth-Related Oncogene-Î± by Human Eosinophils. Journal of Immunology, 2003, 170, 5309-5316.	0.8	31
110	Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Modern Pathology, 2011, 24, 708-719.	5.5	31
111	A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. Journal of Nuclear Medicine, 2016, 57, 1865-1871.	5.0	31
112	Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate, 2005, 64, 29-39.	2.3	30
113	Preclinical Characterization of 3Î²-(N-Acetyl <scp>l</scp>-cysteine methyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 587 Td Prostate Cancer. Journal of Medicinal Chemistry, 2016, 59, 4551-4562.	6.4	30
114	Lipopolysaccharide-binding protein is produced in the epididymis and associated with spermatozoa and prostasomes. Journal of Reproductive Immunology, 2005, 66, 33-43.	1.9	29
115	A Compartmental Model for Biokinetics and Dosimetry of ¹⁸F-Choline in Prostate Cancer Patients. Journal of Nuclear Medicine, 2012, 53, 985-993.	5.0	29
116	Trypsin-2 Degrades Human Type II Collagen and Is Expressed and Activated in Mesenchymally Transformed Rheumatoid Arthritis Synovitis Tissue. American Journal of Pathology, 2005, 167, 1119-1124.	3.8	28
117	Immunohistochemical detection of tyrosine phosphatase SHPâ€1 predicts outcome after radical prostatectomy for localized prostate cancer. International Journal of Cancer, 2010, 126, 2296-2307.	5.1	28
118	Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy. EJNMMI Research, 2014, 4, 58.	2.5	28
119	Circulating Tumor Cells as a Marker for Progressionâ€free Survival in Metastatic Castrationâ€naÃ¯ve Prostate Cancer. Prostate, 2017, 77, 849-858.	2.3	28
120	Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: Possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma. Experimental Cell Research, 2008, 314, 914-926.	2.6	27
121	Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. European Urology Focus, 2016, 2, 540-546.	3.1	27
122	Scavenging of Labile Heme by Hemopexin Is a Key Checkpoint in Cancer Growth and Metastases. Cell Reports, 2020, 32, 108181.	6.4	27
123	Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation. BJU International, 2006, 98, 189-196.	2.5	25
124	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. EBioMedicine, 2021, 65, 103269.	6.1	25
125	Anti-Thrombin Is Expressed in the Benign Prostatic Epithelium and in Prostate Cancer and Is Capable of Forming Complexes with Prostate-Specific Antigen and Human Glandular Kallikrein 2. American Journal of Pathology, 2002, 161, 2053-2063.	3.8	24
126	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	5.4	24

#	Article	IF	Citations
127	Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial. BJU International, 2021, 127, 361-368.	2.5	24
128	Immunoreactive Delta Sleep-Inducing Peptide in Pituitary Adrenocorticotropin/Alpha-Melanotropin Cells and Adrenal Medullary Cells of the Pig. Neuroendocrinology, 1987, 45, 298-304.	2.5	23
129	High Expression of Midkine in the Airways of Patients with Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 935-942.	2.9	23
130	Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer. PLoS ONE, 2015, 10, e0133449.	2.5	23
131	Radioimmunotherapy for Prostate Cancerâ€"Current Status and Future Possibilities. Seminars in Nuclear Medicine, 2016, 46, 165-179.	4.6	23
132	90-Day readmission after radical prostatectomyâ€"a prospective comparison between robot-assisted and open surgery. Scandinavian Journal of Urology, 2019, 53, 26-33.	1.0	23
133	Generalization of prostate cancer classification for multiple sites using deep learning. , 2018, , .		22
134	Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1041-1051.	6.4	22
135	Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissue sections. The Histochemical Journal, 1999, 31, 45-52.	0.6	21
136	Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections. Urology, 2000, 56, 682-688.	1.0	21
137	Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer. Journal of Proteome Research, 2017, 16, 204-216.	3.7	21
138	Emphasizing the role of <scp>Wnt5a</scp> protein expression to predict favorable outcome after radical prostatectomy in patients with lowâ€grade prostate cancer. Cancer Medicine, 2012, 1, 96-104.	2.8	20
139	Plasma Alkylresorcinol Metabolites as Biomarkers for Whole-Grain Intake and Their Association with Prostate Cancer: A Swedish Nested Caseâ€"Control Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 73-83.	2.5	20
140	The Î²2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. Molecular Cancer Research, 2019, 17, 2154-2168.	3.4	20
141	STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population. Scientific Reports, 2020, 10, 13958.	3.3	20
142	Lipopolysaccharideâ€Binding Protein Increases Tollâ€like Receptor 4â€"Dependent Activation by NontypeableHaemophilus influenzae. Journal of Infectious Diseases, 2001, 184, 926-930.	4.0	19
143	Automatic registration of multi-modal microscopy images for integrative analysis of prostate tissue sections. BMC Cancer, 2013, 13, 408.	2.6	19
144	Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World Journal of Urology, 2015, 33, 907-916.	2.2	19

#	Article	IF	Citations
145	Global expression of AMACR transcripts predicts risk for prostate cancer â€“ a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. BMC Urology, 2016, 16, 10.	1.4	19
146	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	3.0	19
147	Î32-MSH immunoreactivity in the human heart. Life Sciences, 1989, 45, 787-792.	4.3	18
148	Interobserver variability in the pathological assessment of radical prostatectomy specimens: Findings of the Laparoscopic Prostatectomy Robot Open (LAPPRO) study. Scandinavian Journal of Urology, 2014, 48, 160-167.	1.0	18
149	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	1.9	18
150	Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients. Journal of Nuclear Medicine, 2020, 61, 671-675.	5.0	18
151	Introducing PIONEER: a project to harness big data in prostate cancer research. Nature Reviews Urology, 2020, 17, 351-362.	3.8	18
152	PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population. Scandinavian Journal of Urology and Nephrology, 2010, 44, 378-383.	1.4	17
153	An Artificial Intelligenceâ€“based Support Tool for Automation and Standardisation of Gleason Grading in Prostate Biopsies. European Urology Focus, 2020, 7, 995-1001.	3.1	17
154	Midkine Is Part of the Antibacterial Activity Released at the Surface of Differentiated Bronchial Epithelial Cells. Journal of Innate Immunity, 2013, 5, 519-530.	3.8	16
155	Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study. Prostate Cancer, 2014, 2014, 1-8.	0.6	16
156	Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3412-3418.	6.4	16
157	Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens. Urology, 2014, 83, 511.e1-511.e7.	1.0	15
158	Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting. International Journal of Cancer, 2017, 141, 1170-1180.	5.1	15
159	Bringing Greater Accuracy to Europeâ€™s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomedicine Hub, 2020, 5, 1-42.	1.2	15
160	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	2.5	15
161	Immunoreactive Delta Sleep-Inducing Peptide Secretion from Mouse Dissociated, Anterior Pituitary Cells: Regulation by Corticotropin-Releasing Factor and Arginine Vasopressin. Neuroendocrinology, 1989, 50, 564-569.	2.5	14
162	The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. European Urology, 2006, 49, 758-759.	1.9	14

#	Article	IF	Citations
163	The fungal metabolite galiellalactone interferes with the nuclear import of NF-ÎºB and inhibits HIV-1 replication. Chemico-Biological Interactions, 2014, 214, 69-76.	4.0	14
164	Vesicourethral Anastomotic Stenosis After Open or Robot-assisted Laparoscopic Retropubic Prostatectomyâ€"Results from the Laparoscopic Prostatectomy Robot Open Trial. European Urology Focus, 2021, 7, 317-324.	3.1	14
165	Expression and Immunolocalisation of Neutral Endopeptidase in Prostate Cancer. European Urology, 2003, 44, 415-422.	1.9	13
166	Low expression of SHP-2 is associated with less favorable prostate cancer outcomes. Tumor Biology, 2013, 34, 637-642.	1.8	13
167	Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study. European Urology Focus, 2016, 2, 547-552.	3.1	13
168	Bringing Onco-Innovation to Europeâ€™s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. Cancers, 2021, 13, 583.	3.7	13
169	Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunology, Immunotherapy, 2021, 70, 3155-3166.	4.2	13
170	Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. Targeted Oncology, 2021, 16, 357-367.	3.6	13
171	Delta Sleep-inducing Peptide-like Immunoreactivity in Pituitary ACTH/MSH and Adrenal Medullary Cells. Annals of the New York Academy of Sciences, 1987, 512, 476-479.	3.8	12
172	Targeting Free Prostate-Specific Antigen forIn VivoImaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 243-251.	1.0	12
173	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. European Urology, 2015, 68, 1076-1082.	1.9	12
174	Psychological Well-being and Private and Professional Psychosocial Support After Prostate Cancer Surgery: A Follow-up at 3, 12, and 24 Months After Surgery. European Urology Focus, 2016, 2, 418-425.	3.1	12
175	Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).. Journal of Clinical Oncology, 2020, 38, 82-82.	1.6	12
176	Immunocytochemical demonstration of DSIP-like immunoreactivity in the hypothalamus of the rat. Peptides, 1991, 12, 1155-1159.	2.4	11
177	Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men. European Journal of Nutrition, 2018, 57, 2595-2606.	3.9	11
178	Intake of individual fatty acids and risk of prostate cancer in the European prospective investigation into cancer and nutrition. International Journal of Cancer, 2020, 146, 44-57.	5.1	11
179	A nutrient-wide association study for risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition and the Netherlands Cohort Study. European Journal of Nutrition, 2020, 59, 2929-2937.	3.9	11
180	Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities. Current Opinion in Endocrine and Metabolic Research, 2020, 10, 36-42.	1.4	11

#	Article	IF	Citations
181	Urinary continence recovery and oncological outcomes after surgery for prostate cancer analysed by risk category: results from the LAParoscopic prostatectomy robot and open trial. World Journal of Urology, 2021, 39, 3239-3249.	2.2	11
182	PSA and Prostate Cancer Screening: The Challenge of the New Millennium. European Urology, 2007, 52, 1284-1286.	1.9	10
183	The pentraxin serum amyloid P component is found in the male genital tract and attached to spermatozoa. Journal of Developmental and Physical Disabilities, 2008, 31, 508-517.	3.6	10
184	Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. World Journal of Urology, 2012, 30, 785-794.	2.2	10
185	Identification of plasma protein profiles associated with risk groups of prostate cancer patients. Proteomics - Clinical Applications, 2014, 8, 951-962.	1.6	10
186	Analysis of plasma from prostate cancer patients links decreased carnosine dipeptidase 1 levels to lymph node metastasis. Translational Proteomics, 2014, 2, 14-24.	1.2	10
187	Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO. Acta OncolÃ³gica, 2016, 55, 1467-1476.	1.8	10
188	Habits and self-assessed quality of life, negative intrusive thoughts and depressed mood in patients with prostate cancer: a longitudinal study. Scandinavian Journal of Urology, 2017, 51, 353-359.	1.0	10
189	IMAGINEâ€"IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines. European Urology, 2021, 79, 173-176.	1.9	10
190	Expression of the TPÎ± and TPÎ² isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential. Oncotarget, 2016, 7, 73171-73187.	1.8	10
191	Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution. Nuclear Medicine and Biology, 2015, 42, 375-380.	0.6	9
192	Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. European Urology Oncology, 2021, 4, 49-55.	5.4	9
193	Quantification of microRNA editing using two-tailed RT-qPCR for improved biomarker discovery. Rna, 2021, 27, 1412-1424.	3.5	9
194	Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. Journal of Urology, 2021, 206, 914-923.	0.4	9
195	Low Î²2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. Oncotarget, 2016, 7, 1878-1894.	1.8	9
196	Next-generation Prostate-specific Antigen Test: Ready To Use?. European Urology, 2013, 64, 700-702.	1.9	8
197	Androgen Receptor Polymorphism-Dependent Variation in Prostate-Specific Antigen Concentrations of European Men. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2048-2056.	2.5	8
198	Role of serum response factor expression in prostate cancer biochemical recurrence. Prostate, 2018, 78, 724-730.	2.3	8

#	Article	IF	Citations
199	Agreement between patient reported outcomes and clinical reports after radical prostatectomy - a prospective longitudinal study. BMC Urology, 2019, 19, 35.	1.4	8
200	New Hope in Prostate Cancer Precision Medicine? miRNA Replacement and Epigenetics. Clinical Cancer Research, 2019, 25, 2679-2681.	7.0	8
201	Expression of tSTAT3, pSTAT3 727 , and pSTAT3 705 in the epithelial cells of hormoneâ€naÃ¯ve prostate cancer. Prostate, 2019, 79, 784-797.	2.3	8
202	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
203	COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials, 2021, 22, 209.	1.6	8
204	Biosynthesis and processing of delta sleep-inducing peptide-like precursors in primary cultures of mouse anterior pituitary cells. FEBS Journal, 1990, 190, 131-137.	0.2	7
205	Relationship between serum response factor and androgen receptor in prostate cancer. Prostate, 2015, 75, 1704-1717.	2.3	7
206	Social constraints and psychological wellâ€being after prostate cancer: A followâ€up at 12 and 24Âmonths after surgery. Psycho-Oncology, 2018, 27, 668-675.	2.3	7
207	Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO. European Urology Open Science, 2020, 20, 54-61.	0.4	7
208	Amidated joining peptide in the human pituitary, gut, adrenal gland and bronchial carcinoids. Immunocytochemical and immunochemical evidence. Peptides, 1990, 11, 149-161.	2.4	6
209	Increased presence of cells containing transforming growth factor alpha (TGF-Î±) in ulcerative colitis, both during active inflammation and in remission. European Journal of Gastroenterology and Hepatology, 2000, 12, 761-766.	1.6	6
210	TCF7L2 type 2 diabetes risk variant, lifestyle factors, and incidence of prostate cancer. Prostate, 2014, 74, 1161-1170.	2.3	6
211	Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scandinavian Journal of Urology, 2016, 50, 255-259.	1.0	6
212	Automatic Gleason grading of H and E stained microscopic prostate images using deep convolutional neural networks. , 2017, , .		6
213	How badly did it hit? Self-assessed emotional shock upon prostate cancer diagnosis and psychological well-being: a follow-up at 3, 12, and 24 months after surgery. Acta OncolÃ³gica, 2017, 56, 984-990.	1.8	6
214	Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing. Progress in Preventive Medicine (New York, N Y), 2017, 2, e006.	0.7	6
215	Associations between intraoperative factors and surgeonsâ€™ self-assessed operative satisfaction. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 61-68.	2.4	6
216	Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2021, 39, 11-11.	1.6	6

#	Article	IF	Citations
217	Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer. European Urology Open Science, 2021, 30, 25-33.	0.4	6
218	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. European Urology Focus, 2021, 7, 943-946.	3.1	6
219	Circulating Tumour Cells as Surrogate Biomarkers in Castration-Resistant Prostate Cancer Trials. European Urology, 2011, 60, 905-907.	1.9	5
220	Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation. Therapeutic Advances in Urology, 2017, 9, 127-136.	2.0	5
221	A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Scandinavian Journal of Urology, 2019, 53, 312-318.	1.0	5
222	Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease.. Journal of Clinical Oncology, 2020, 38, 87-87.	1.6	5
223	Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. European Urology Open Science, 2022, 41, 126-133.	0.4	5
224	PROQUR: A tool for quality control, epidemiological surveillance, patient follow-up and clinical research activities related to prostate cancer. Acta OncolÃ³gica, 2005, 44, 628-632.	1.8	4
225	Topical steroids do not downregulate expression of growth-related oncogene-Î± in nasal polyps. Acta Oto-Laryngologica, 2006, 126, 375-380.	0.9	4
226	Corrigendum re: â€œUrinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trialâ€•[Eur Urol 2015;68:216â€“25]. European Urology, 2017, 72, e81-e82.	1.9	4
227	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open, 2021, 11, e040531.	1.9	4
228	First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2019, 37, 5006-5006.	1.6	4
229	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
230	The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.. Journal of Clinical Oncology, 2022, 40, 89-89.	1.6	4
231	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. BMJ Open, 2022, 12, e058267.	1.9	4
232	Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.. Journal of Clinical Oncology, 2022, 40, 5066-5066.	1.6	4
233	Human pheochromocytoma cells studied in culture contain large amounts of DSIP-like material. Peptides, 1991, 12, 1077-1083.	2.4	3
234	Accurate prediction tools in prostate cancer require consistent assessment of included variables. Scandinavian Journal of Urology, 2016, 50, 260-266.	1.0	3

#	Article	IF	Citations
235	The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development. PharmacoEconomics - Open, 2021, 5, 77-88.	1.8	3
236	Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. European Urology Focus, 2021, , .	3.1	3
237	Identification of a serum biomarker signature associated with metastatic prostate cancer. Proteomics - Clinical Applications, 2021, 15, 2000025.	1.6	3
238	A retrospective study assessing the accuracy of [18F]â€“fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection. Scandinavian Journal of Urology, 2021, 55, 293-297.	1.0	3
239	Translating Prostate Cancer Working Group 2 (PCWG2) progression criteria into a quantitative response biomarker in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 170-170.	1.6	3
240	Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.. Journal of Clinical Oncology, 2017, 35, 212-212.	1.6	3
241	Copy Number Variants in the Kallikrein Gene Cluster. PLoS ONE, 2013, 8, e69097.	2.5	2
242	Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. European Urology, 2015, 67, 349-350.	1.9	2
243	A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer. BMC Medical Imaging, 2018, 18, 8.	2.7	2
244	Hospital readmissions after limited vs. extended lymph node dissection during open and robot-assisted radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 5.e1-5.e8.	1.6	2
245	Do negative intrusive thoughts at diagnosis predict impaired quality of life, depressed mood and waking up with anxiety 3, 12 and 24 months after radical prostatectomy? â€“ a longitudinal study. Scandinavian Journal of Urology, 2020, 54, 220-226.	1.0	2
246	Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. European Urology Focus, 2021, 7, 178-185.	3.1	2
247	Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2021, 39, 5068-5068.	1.6	2
248	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	2.3	2
249	Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naÃ¯ve prostate cancer. Pathology Research and Practice, 2022, 232, 153811.	2.3	2
250	Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer. Nuclear Medicine and Molecular Imaging, 2022, 56, 188-195.	1.0	2
251	â€œA Robot Saved My Lifeâ€• Is It a Myth?. European Urology, 2012, 62, 775-776.	1.9	1
252	Modeling Costs for Prostate Surgery: Are We Close to Reality?. European Urology, 2013, 64, 370-371.	1.9	1

#	Article	IF	Citations
253	Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial. European Urology, 2015, 67, 348-349.	1.9	1
254	Re: The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. European Urology, 2016, 70, 700.	1.9	1
255	Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better. Biomedicine Hub, 2017, 2, 1-7.	1.2	1
256	Re: 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. European Urology, 2020, 78, 632.	1.9	1
257	European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management. European Urology, 2020, 77, 397-399.	1.9	1
258	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology, 2021, , .	1.0	1
259	The prognostic impact of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite.. Journal of Clinical Oncology, 2017, 35, 47-47.	1.6	1
260	ProBio II: An adaptive and randomized multi-arm biomarker driven phase 2 study in men with castrate resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2018, 36, TPS397-TPS397.	1.6	1
261	Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.. Journal of Clinical Oncology, 2017, 35, 5028-5028.	1.6	1
262	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clinical Genitourinary Cancer, 2022, , .	1.9	1
263	Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2022, , .	1.9	1
264	Lymph swelling after radical prostatectomy and pelvic lymph node dissection. BJU International, 2022, 129, 695-698.	2.5	1
265	Increasing rates of urinary and bloodstream infections following transrectal prostate biopsy in South Sweden. BJU International, 2022, , .	2.5	1
266	EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA). European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3328-3329.	6.4	1
267	Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections. Journal of Histochemistry and Cytochemistry, 2016, 64, 311-322.	2.5	0
268	Making Predictive Biomarkers Readily Available. European Urology, 2016, 70, 609-610.	1.9	0
269	Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele. Cancer Causes and Control, 2017, 28, 227-233.	1.8	0
270	Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Scandinavian Journal of Urology, 2020, 54, 263-264.	1.0	0

#	Article	IF	Citations
271	A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned. Journal of Urology, 2021, 205, 1145-1152.	0.4	0
272	Reply by Authors. Journal of Urology, 2021, 206, 923-923.	0.4	0
273	Increase in bone scan index during abiraterone treatment in relation to reduced survival in mCRPC patients.. Journal of Clinical Oncology, 2014, 32, 244-244.	1.6	0
274	Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5044-5044.	1.6	0
275	Automated bone scan index as a quantitative imaging biomarker indicative of efficacy to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 226-226.	1.6	0
276	Automated bone scan index as an imaging biomarker in metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223.. Journal of Clinical Oncology, 2016, 34, e16600-e16600.	1.6	0
277	Bone Scan Index as an imaging biomarker to predict overall survival in the Zeus/SPCG11 study.. Journal of Clinical Oncology, 2016, 34, e16599-e16599.	1.6	0
278	The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?. Journal of Clinical Oncology, 2016, 34, 5024-5024.	1.6	0
279	Prognostic significance of professional antigen presenting cells according to morphological subtype of periampullary adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 121-121.	1.6	0
280	The prognostic impact of CD3, CD8, FoxP3, and IL17 tumor-infiltrating immune cells in periampullary cancer differs by morphological type and adjuvant chemotherapy.. Journal of Clinical Oncology, 2017, 35, 53-53.	1.6	0
281	Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.. Journal of Clinical Oncology, 2017, 35, e16537-e16537.	1.6	0
282	Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 311-23.	1.0	0
283	Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiongâ€™s Letter to the Editor re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650â€“60. European Urology, 2021, 81, e43-e43.	1.9	0
284	Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€“derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer. European Urology, 2022, , .	1.9	0
285	Learning curve for robot-assisted laparoscopic radical prostatectomy in a large prospective multicentre study. Scandinavian Journal of Urology, 2022, 56, 182-190.	1.0	0